Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.

The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

The invention relates to quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds, processes for preparing quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds, antimicrobial coating compositions comprising quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds and method of treating a surface with said compositions to provide a durable, antimicrobial-treated surface.

The present invention relates to an inorganic-organic hybrid compound as ionic compound, composed of an inorganic cation and of an organic active ingredient anion and also, optionally, of an organic fluorescent dye anion.

The present invention relates to crystallizates of the pure aminoalkylenephosphonic acid DTPMP in three crystal polymorphs and to a process for obtaining solid crystalline DTPMP by a preferably one-stage crystallization from an aqueous product mixture comprising DTPMP, wherein the process comprises the following process steps: (a) introducing seed crystals comprising DTPMP into an aqueous crude product comprising DTPMP with a total proportion in the range from 10 to 65 percent by mass up to a suspension density in the range from 1% to 25%; (b) introducing kinetic energy into the aqueous crude product to precipitate a crystallizate containing DTPMP as pure acid with a total content of at least 75% by mass; and (c) removing the crystallizate formed from the aqueous crude product by sedimentation and/or filtration, such that DTPMP is obtained as a solid end product in the form of a crystallizate.

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.

The invention provides in part, conjugate compounds. The invention also provides synthesis methods for making the compounds, and uses of the compounds.

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.

The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with .sup.68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.

##STR00001##

Described herein are compositions including a silanol compound that is suitably synthesized, stored, and coated from an aqueous solution. Once coated and cured on a suitable surface, the aqueous silanol compositions result in cleanable and abrasion resistant surfaces, such as dry-erase surfaces that release permanent marker by rubbing with a dry cloth or towel. Also disclosed herein are methods of making the silanol compounds, methods of making cleanable substrates, and cleanable substrates suitably formed using the disclosed methods.